NovoTTF: where to go from here?
作者信息
Cloughesy Timothy F, Lassman Andrew B
机构信息
UCLA Neuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, USA.
出版信息
Neuro Oncol. 2017 May 1;19(5):605-608. doi: 10.1093/neuonc/nox014.
Abstract
摘要
相似文献
1
NovoTTF: where to go from here?
Neuro Oncol. 2017 May 1;19(5):605-608. doi: 10.1093/neuonc/nox014.
2
Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
Semin Oncol. 2014 Jun;41 Suppl 4:S1-14. doi: 10.1053/j.seminoncol.2014.03.011. Epub 2014 Mar 19.
3
Delayed response and survival from NovoTTF-100A in recurrent GBM.
Med Oncol. 2013 Mar;30(1):338. doi: 10.1007/s12032-012-0338-1. Epub 2013 Jan 10.
4
NovoTTF-100A: a new treatment modality for recurrent glioblastoma.
Expert Rev Neurother. 2012 Aug;12(8):895-9. doi: 10.1586/ern.12.80. Epub 2012 Jun 19.
5
A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields.
Semin Oncol. 2013 Dec;40(6):S2-4. doi: 10.1053/j.seminoncol.2013.10.002. Epub 2013 Oct 10.
6
Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16.
7
Tumor Treating Fields in Neuro-Oncological Practice.
Curr Oncol Rep. 2017 Aug;19(8):53. doi: 10.1007/s11912-017-0611-8.
8
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
World J Surg Oncol. 2014 May 22;12:162. doi: 10.1186/1477-7819-12-162.
9
First-in-class antimitotic device approved for glioblastoma.
Oncology (Williston Park). 2011 May;25(6):546.
10
Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.
Semin Oncol. 2014 Oct;41 Suppl 6:S25-34. doi: 10.1053/j.seminoncol.2014.09.008. Epub 2014 Sep 16.
引用本文的文献
1
Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions.
Int J Mol Sci. 2024 Oct 7;25(19):10765. doi: 10.3390/ijms251910765.
2
Gene Expression Patterns Associated with Survival in Glioblastoma.
Int J Mol Sci. 2024 Mar 25;25(7):3668. doi: 10.3390/ijms25073668.
3
Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.
Cancers (Basel). 2024 Mar 25;16(7):1276. doi: 10.3390/cancers16071276.
4
Medical Device Advances in the Treatment of Glioblastoma.
Cancers (Basel). 2022 Oct 29;14(21):5341. doi: 10.3390/cancers14215341.
5
Updates in IDH-Wildtype Glioblastoma.
Neurotherapeutics. 2022 Oct;19(6):1705-1723. doi: 10.1007/s13311-022-01251-6. Epub 2022 May 31.
6
Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients.
Cancers (Basel). 2021 Oct 26;13(21):5358. doi: 10.3390/cancers13215358.
7
Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis.
Neurooncol Pract. 2021 Apr 20;8(4):426-440. doi: 10.1093/nop/npab026. eCollection 2021 Aug.
8
Current usage of tumor treating fields for glioblastoma.
Neurooncol Adv. 2020 Jun 4;2(1):vdaa069. doi: 10.1093/noajnl/vdaa069. eCollection 2020 Jan-Dec.
9
Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Oncologist. 2019 Dec;24(12):e1426-e1436. doi: 10.1634/theoncologist.2017-0603. Epub 2019 Aug 23.
10
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.
本文引用的文献
1
The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.
Neuro Oncol. 2016 Aug;18(8):1129-36. doi: 10.1093/neuonc/now102. Epub 2016 May 13.
2
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.
3
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15.
4
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.
5
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.
6
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275. doi: 10.1007/s00701-005-0707-z. Epub 2006 Feb 17.
7
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
J Neurosurg. 1978 Sep;49(3):333-43. doi: 10.3171/jns.1978.49.3.0333.
Zotero 插件